Durvalumab plus rintatolimod for metastatic pancreatic cancer
Treatments studied
Part of Cancer, Digestive system, Hormones & metabolism clinical trials.
This early-phase study tests whether adding rintatolimod to durvalumab can improve outcomes for people with metastatic pancreatic cancer. It aims to see if this combination can better activate the immune system against the cancer after initial chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed metastatic pancreatic cancer from lab tests (biopsy or fluid sample).
- Your cancer was stable after at least 8 cycles of FOLFIRINOX chemotherapy, and you start within 6 weeks of the last dose.
- You can provide tissue from an accessible metastatic spot for lab testing.
- Your blood tests and overall health are within study limits (immune/inflammation index, kidney and liver function, and adequate blood counts).
- You have good daily function (WHO performance status 0–1), and can travel for study visits for at least 12 weeks.
- You must be able to use effective birth control and be willing to give signed informed consent.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three chemotherapy drugs (mFOLFIRINOX) along with anlotinib (a targeted therapy) and sintilimab (an immunotherapy) for people with advanced pancreatic cancer who have not had prior treatment. The goal is to see if this combination can help shrink tumors or slow the disease.
This trial tests a combination of a targeted immune therapy (Adebrelimab) with three chemotherapy drugs for people with metastatic pancreatic cancer who haven't had any treatment yet. The goal is to see if this combination can shrink tumors and help people live longer.
This Phase 2 study tests whether adding propranolol to durvalumab and tremelimumab along with chemotherapy can help control advanced pancreatic cancer, liver cancer, or bile duct cancer. It aims to shrink tumors and help people live longer or feel better when the cancer can’t be cured with surgery or local treatment.
This Phase 2 trial studies a new treatment plan that combines RMT with durvalumab and chemotherapy in people with untreated advanced lung adenocarcinoma. It aims to improve outcomes by helping the immune system and fighting cancer cells together.
This trial combines the immunotherapy drug sintilimab with chemotherapy and radiation for people with inoperable locally advanced pancreatic cancer who have not received prior systemic treatment. The goal is to see if this combination shrinks tumors and improves outcomes.
This trial studies durvalumab (an immune therapy) combined with chemotherapy to treat advanced solid tumors that have grown despite prior standard treatment or have no proven standard option. It aims to improve control of the cancer and help people live longer.
Hear when a new Metastatic Pancreatic Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.